ClinicalTrials.gg
CompletedNCT06644482Updated Jun 24, 2025

Exercise as Treatment for Patients With Inclusion Body Myositis

An interventional study of Exercise group in a hospital setting in Inclusion Body Myositis (IBM) and Feasibility Study, sponsored by Oslo University Hospital. Completed at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

There is little knowledge about exercise for patients with inclusion body myositis (IBM). Patients with IBM have limited access to rehabilitation and physiotherapy resources, despite a significant need for these services due to the progressive nature of the condition, which leads to a gradual decline in physical function. The purpose of the project is to develop and implement a 16-week exercise intervention at Oslo University Hospital (OUS) for patients with IBM living in Oslo and the surrounding area. The exercise sessions will take place once a week at OUS, under the guidance of physiotherapists with extensive clinical experience with this patient group. Patients are encouraged to exercise at home at least once a week between sessions at OUS to achieve sufficient amount of exercise that normally will improve physical fitness. The feasibility and benefits of the exercise intervention will be evaluated using various methods, such as focus group interviews, physical tests, and questionnaires. The study will also provide valuable insight into whether exercise can lead to improvements in muscle strength, fitness, and balance in patients with IBM.

02

Conditions studied

  • Inclusion Body Myositis (IBM)
  • Feasibility Study

Keywords

  • exercise
  • feasibility study
03

In context

Myositis, Inclusion Body

65 studies on the registry are indexed under Myositis, Inclusion Body; 10 are open to participants now.

This study's enrollment of 15 is below the median of 30 across 42 interventional studies indexed under Myositis, Inclusion Body.

Browse Myositis, Inclusion Body studies →

Lead sponsor

Oslo University Hospital is the lead sponsor of 835 studies on the registry; 148 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IBM diagnosis
  • Able to walk with aids

Exclusion criteria

Exclusion Criteria

-Unable to understand and write Norwegian

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    Exercise group in a hospital

    Participants will take part in an exercise group delivered once a week in a hospital setting for 16 weeks

    Other: Exercise group in a hospital setting

Interventions

  • OtherExercise group in a hospital setting

    Participants will exercise in a group once a week for 16 weeks in a hospital setting.

06

What researchers measure

Primary outcomes

  1. Feasibility: proportion completing the exercise intervention

    Proportion of included participants completing the exercise intervention

    Time frame: Baseline to 16 week

  2. Feasibility: proportion of received exercise diaries

    Proportion of received exercise diaries (0-16 per participant)

    Time frame: Baseline to 16 weeks

  3. Recruitment: proportion enrolled

    Proportion of eligible patients enrolled

    Time frame: Baseline

  4. Feasibility: exercise diaries

    The participants will log experiences with the intervention (e.g. completed/not completed exercises, reasons for any non-completion, other training activities, barriers/facilitators).

    Time frame: Baseline to 16 week

  5. Feasibility: proportion of patients completing physical fitness tests

    Proportion of patients completing physical fitness tests

    Time frame: Baseline and 17 weeks

  6. Feasibilty: Focus group interview

    Participants will participate in focus group interviews exploring the experiences of the intervention

    Time frame: 17 weeks

Secondary outcomes

  1. Changes in walking distance

    Assessed by the 2 minutes walking test. Changes in walking distance measured as meters.

    Time frame: Baseline and 17 weeks

  2. Changes in functional lower extremity strength

    The patients are to stand up and sit down from a chair as many times as they can within 30 seconds, and the total number of times is recorded.

    Time frame: Baseline and 17 weeks

  3. Changes in muscle endurance

    Assessed by the Functional Index- 2 in three muscle groups; shoulder flexors (maximum 60 repetitions), neck flexors (maximum 30 repetitions) and hip flexors (maximum 60 repetitions).

    Time frame: Baseline and 17 weeks

  4. Changes in muscle strength

    Assessed by the Manual Muscle test - 8 (MMT - 8), which includes unilateral testing of muscle strength in 8 eight muscle groups; (Deltoid, Biceps, Wrist extensors, Quadriceps, Ankle dorsiflexors, Neck flexors, Gluteus medius and Gluteus maximux). Each muscle group is scored on a 0-10-point scale (10=best score). The total MMT - 8 will be calculated (0-80, 80=best score).

    Time frame: Baseline and 17 weeks

  5. Changes in grip stength

    Assessed by hydraulic hand dynamometer (Baseline). Change in grip strength is recorded in kilograms.

    Time frame: Baseline and 17 weeks

  6. Change in the Berg Balance Scale

    The Berg Balance Scale (BBS) is a 14-item objective measure that assesses static and dynamic balance and fall risk in adults. Each item is scored on a 5-point ordinal scale ranging from 0 to 4, with 0 indicating an inability to complete the task entirely and 4 indicating an ability to complete the task criterion.The total score ranges from 0-52 (52 indicates best score).

    Time frame: Baseline and 17 weeks

  7. Change in the Inclusion Body Myositis Functional Rating Scale (IBMFRS)

    The IBMFRS consists of 10 questions about a patient's ability to perform daily activities (including walking, dressing, swallowing and handling utensils). Each question is answered using a number from 0-4. The numbers are added up to give the total score ranging from 0 to 40, with 40 being the best possible score

    Time frame: Baseline and 17 weeks

  8. Change in the Health Assessment Questionnaire (HAQ) score

    Change in the last week disability on the total HAQ score (0-3, 0 indicates best possible function). The HAQ comprises 30 questions, covering eight functional ability domains related to daily living during the past week (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities). The score ranges from 0-3 (0 indicates no disability, 3 indicates severe disability) in each domain, of which the total CHAQ is calculated.

    Time frame: Baseline and 17 weeks

  9. Change in Patient Specific Functional Scale (PSFS)

    The patients will identify 3-5 important activities they are unable to perform or have difficulty with due to inclusion body myositis. The patients are then asked to rate the current level of difficulty associated with each activity on an 11-point scale, from 0 (not able to perform the activity) to 10 (no problems).

    Time frame: Baseline and 17 weeks

  10. Change in self-reported physical activity

    Assessed by the International Physical Activity Questionnaire-Short form (IPAQ-SF). Change in time (minutes per week/day) and Metabolic Equivalent of Task (MET-minutes per week/day) spent on sitting, walking, and moderate- and vigorous intensity physical activity the last week. METs are calculated by using the corresponding MET-values for walking (3.3 MET), and moderate-(4.0 MET) and vigorous (8.0 MET) intensity physical activity.

    Time frame: Baseline and 17 weeks

  11. Change in Health-Related Quality of Life

    Assessed by the Short Form Health Survey (SF36) which comprises 36 questions covering the areas of physical function, role limitations (physical), pain, general health perception, energy and fatigue (vitality), social function, role limitations (emotional), and mental health. The results are recoded so that the final score for each area ranges from 0 to 100, where 100 indicates the best possible health.

    Time frame: Baseline and 17 weeks

Other outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety].

    Patients will log 1) total of falls during the training period and 2) total number of near-falls during the training period.

    Time frame: Baseline to 16 week

  2. Incidence of Treatment-Emergent Adverse Events [Tolerability]- pain.

    Self-reported pain will be assessed by numeric rating scale ranging from 0 (no pain) to 10 (worst pain)

    Time frame: Baseline to 16 week

  3. Incidence of Treatment-Emergent Adverse Events [Tolerability]- muscle fatigue

    Self-reported muscle fatigue will be assessed by numeric rating scale ranging from 0 (no muscle fatigue) to 10 (worst muscle fatigue)

    Time frame: Baseline to 16 week

  4. Incidence of Treatment-Emergent Adverse Events [Tolerability]- muscle fatigue

    Self-reported muscle soreness will be assessed by numeric rating scale ranging from 0 (no muscle soreness) to 10 (worst muscle soreness)

    Time frame: Baseline to 16 week

  5. Incidence of Treatment-Emergent Adverse Events [Tolerability]- fatigue

    Self-reported fatigue will be assessed by numeric rating scale ranging from 0 (no fatigue) to 10 (worst fatigue)

    Time frame: Baseline to 16 week

07

Study locations

1 site
  • Oslo University Hospital
    Oslo, Oslo County 0424, Norway
08

References and documents

Individual participant data

Plan to share: No — Data can be made available on reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2025 to primary completion in May 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 16, 2024
StartActual
Jan 6, 2025
Primary completionActual
May 28, 2025
CompletionActual
May 28, 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06644482
Collaborators
The Dam Foundation, The Norwegian Rheumatism Association
Responsible party
Kristine Risum (Senior physioterapist, Oslo University Hospital) — Principal investigator
First posted
Oct 16, 2024
Start date
Jan 6, 2025
Primary completion
May 28, 2025
Completion
May 28, 2025
Last update
Jun 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion